Objectives: This study aims to evaluate the effects of DuraGraft(R), an endothelial protective solution, in comparison to heparinized normal saline, on the patency of saphenous vein grafts (SVGs) in patients undergoing coronary artery bypass grafting (CABG). Patients and methods: Between December 2019 and May 2021, a total of 30 male patients (mean age: 41.7+/-3.2 years; range, 33 to 45 years) who underwent CABG with at least one SVG were included in the study. Saphenous veins were harvested using the open technique and stored at room temperature in either DuraGraft(R) or heparinized saline. At one-year follow-up, symptomatic patients underwent coronary computed tomography angiography (CTA). The patients were divided into two groups based on their admission dates. Those who received the DuraGraft(R) were assigned to the intervention group (Group 1, n=14), while patients who received heparinized normal saline solution were assigned to the control group (Group 2, n=16). A total of 67 grafts from 30 patients were analyzed. Results: One-year angiographic evaluations showed no significant difference in graft patency between the two groups (p>0.05). There was no significant difference in segmental diameter reduction (p=0.483). However, venous wall thickening was significantly less in the DuraGraft(R) group, whereas diffuse wall thickening was observed in the control group (p=0.020). Conclusion: The reduction in venous wall thickening in the DuraGraft(R) group in our study suggests a possible long-term benefit. However, due to the lack of extended follow-up data, these findings should be interpreted with caution.